Kalaris Therapeutics (KLRS) Misses Q2 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KLRS Hot Sheet
Join SI Premium – FREE
Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.61).
For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades STRATTEC Security (STRT) to Buy
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Gartner, Inc. (IT) Tops Q3 EPS by 75c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
